Compare BridgeBio Pharma Inc (BBIO) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs RLX Technology Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while RLX Technology Inc trades at $1.98 (market cap $2.42B). The key difference: BridgeBio Pharma Inc is far larger — about 6.8× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5.05% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | RLX | |
|---|---|---|
Market Cap | $16.36B | $2.42B |
Sector | Health | Technology |
52-Week High | $90.17 | $2.73 |
52-Week Low | $47.29 | $1.79 |
Enterprise Value | $18.14B | $1.04B |
Dividend Yield | — | 5.05% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
